• Targeting p-tau Ser356: NUAK1 Inhibition in Alzheimer’s Mode

  2026-04-24

  Taylor et al. (2023) identify tau phosphorylation at Ser356 as a marker closely linked to Alzheimer’s disease progression and demonstrate that pharmacological NUAK1 inhibition with WZ4003 can specifically decrease this pathogenic tau form in human brain tissue. These findings offer new mechanistic insights for targeted tauopathy interventions and inform translational strategies for disease modeling.

• Prosapogenin A Triggers GSDME-Linked Pyroptosis in ATC via L

  2026-04-24

  This study uncovers how Prosapogenin A induces GSDME-dependent pyroptosis in anaplastic thyroid cancer (ATC) cells through V-ATPase-mediated lysosomal over-acidification and membrane permeabilization. The findings reveal a new therapeutic avenue targeting lysosomal fragility in aggressive cancers and highlight mechanistic contrasts with caspase-centric apoptosis strategies.

• HyperTrap Heparin HP Column: Beyond Purity—Precision in Canc

  2026-04-23

  Explore how the HyperTrap Heparin HP Column empowers reproducible, high-resolution purification for cancer stem cell research. Learn how its advanced chromatography medium enhances experimental rigor and unlocks new avenues for dissecting signaling mechanisms.

• Gold(I) Complex GC002 Induces Necroptosis via TrxR Inhibitio

  2026-04-23

  This study identifies the gold(I) phosphine complex GC002 as a potent inducer of necroptosis in hepatocellular carcinoma (HCC) cells through direct inhibition of thioredoxin reductase (TrxR) and ROS accumulation. The results highlight GC002's superior antitumor activity compared to clinically used agents and its potential as a targeted therapy for HCC.

• CRISPR/Cas9-Mediated Knockout of ABCB1 Reverses Tumor Drug R

  2026-04-22

  This study demonstrates that CRISPR/Cas9 genome editing can specifically disrupt the ABCB1 gene in multidrug-resistant (MDR) cancer cells, significantly restoring their sensitivity to chemotherapeutic agents. The findings provide a technical framework for targeting efflux pump-mediated drug resistance and offer new avenues for functional genomics in cancer research.

• Paclitaxel (Taxol): Precision Dosing and Assay Optimization

  2026-04-22

  Explore Paclitaxel (Taxol) as a microtubule stabilizer with a unique focus on quantitative assay optimization, advanced dosing parameters, and benchmark comparisons in cancer research. This article provides actionable insights for designing robust experiments in oncology.

• SGC-CBP30: Disrupting Super-Enhancer Hijacking in Lung Cance

  2026-04-21

  This article unpacks the emerging role of CREBBP/EP300 bromodomain inhibitors—specifically SGC-CBP30—in targeting super-enhancer hijacking and transcriptional coactivator addiction in early-stage lung adenocarcinoma. Integrating mechanistic evidence, translational workflow guidance, and a competitive landscape analysis, it spotlights SGC-CBP30 as a precision tool for epigenetics and cancer biology research. The discussion advances beyond standard product pages by providing actionable protocol parameters, cross-study insights, and a visionary outlook for translational researchers.

• Novel 14-3-3 Interactors ATG9A and PTOV1 in Cancer Regulatio

  2026-04-21

  This study identifies ATG9A and PTOV1 as novel 14-3-3 binding proteins, unraveling their distinct mechanistic roles in autophagy and oncogenic stability, respectively. Through proteomic and biochemical interrogation, the work illuminates new regulatory axes in cancer biology and suggests tractable pathways for therapeutic exploration.

• Selective Autophagy Regulates IRF3 Stability and Type I IFN

  2026-04-20

  Wu et al. reveal that selective autophagy, mediated by CALCOCO2/NDP52 and regulated by PSMD14, targets the transcription factor IRF3 for degradation in a virus load-dependent manner. This mechanism ensures precise control of type I interferon responses and highlights new layers of innate immune regulation.

• EZH2 Inhibitors Target HPV-Driven Cervical Cancer: New Insig

  2026-04-20

  This study demonstrates that EZH2 inhibitors, particularly EPZ-6438, effectively suppress proliferation and oncogenic signaling in both HPV-positive and negative cervical cancer cells. The findings suggest these agents modulate key tumor suppressor and viral gene pathways, highlighting their potential in epigenetic cancer research.

• Bismuth Subsalicylate (A8382): Protocols for GI Disorder Res

  2026-04-19

  Bismuth Subsalicylate (SKU A8382) provides a high-purity, well-characterized Prostaglandin G/H Synthase 1/2 inhibitor for controlled inflammation and gastrointestinal disorder research. This compound is best suited for cell-based assays, pathway modulation, and translational workflows focused on diarrhea treatment research and upset stomach symptom relief. It is not appropriate for diagnostic or therapeutic use in humans or animals.

• X-Gal (A2539): Precision in Blue-White Screening and Olfacto

  2026-04-18

  Explore the advanced scientific underpinnings of X-Gal in blue-white colony screening and β-galactosidase assays. This article uniquely connects 5-bromo-4-chloro-indolyl-β-D-galactopyranoside utility to emerging insights in olfactory GPCR regulation, offering a deeper perspective for molecular biologists.

• Z-VAD-FMK in Translational Apoptosis Research: Mechanism to

  2026-04-17

  This thought-leadership article demystifies the mechanistic nuances and translational strategy of Z-VAD-FMK (Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone) as a benchmark pan-caspase inhibitor. Integrating primary evidence from recent literature and best-practice workflows, it guides researchers through the strategic application of Z-VAD-FMK in dissecting apoptosis, advancing reproducibility, and interpreting emerging complexities in regulated cell death. The narrative uniquely bridges mechanistic insight with practical translational guidance, establishing new perspectives on apoptosis inhibition for cancer and muscle atrophy studies.

• GLI2 Orchestrates Immune Evasion via WNT and Prostaglandin P

  2026-04-16

  This study reveals that GLI2, a Hedgehog pathway transcription factor, coordinates tumor immune evasion and immunotherapy resistance through WNT ligand production and prostaglandin signaling. By elucidating the signaling crosstalk underlying mesenchymal transformation–driven resistance, the findings provide a mechanistic foundation for targeting GLI2 to enhance immunotherapeutic efficacy.

• CRISPR Screening Reveals MSH2’s Role in Cisplatin Resistance

  2026-04-15

  This study uses a whole-genome CRISPR screen to identify MSH2 as a key mediator of cisplatin resistance in muscle-invasive bladder cancer. The findings suggest that MSH2 protein levels may serve as a biomarker for selecting patients likely to benefit from platinum-based chemotherapy.

460 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page